Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 May;97(18):e0668.
doi: 10.1097/MD.0000000000010668.

Clinical Application of Oral Meglumine Diatrizoate Esophagogram in Screening Esophageal Fistula During Radiotherapy for Esophageal Cancer

Affiliations
Free PMC article
Clinical Trial

Clinical Application of Oral Meglumine Diatrizoate Esophagogram in Screening Esophageal Fistula During Radiotherapy for Esophageal Cancer

Lidan Geng et al. Medicine (Baltimore). .
Free PMC article

Abstract

Introduction: Esophageal fistula is a serious and common complication of radiotherapy for esophageal cancer. Therefore, early diagnosis and treatment is necessary. Because of side effect of barium esophagography, it cannot be used to screening esophageal fistula during radiotherapy. Meglumine diatrizoate is an ionic contrast agent, its adverse reactions were rarely seen when it was used in the body cavity. The purpose of this trial is identified the sensitivity and specificity of oral meglumine diatrizoate in an esophagogram for screening esophageal fistula during radiotherapy.

Methods/design: This trial was a prospective, multicenter, diagnostic clinical trial. A total of 105 patients with esophageal cancer will swallowed meglumine diatrizoate and underwent a radiographic examination weekly during radiotherapy, medical personnel observed the esophageal lesions to determine whether an esophageal fistula formed. If an esophageal fistula was observed, esophagofiberoscopy and/or computer tomography was used to further confirm the diagnosis. And the sensitivity and specificity of meglumine diatrizoate should be calculated for screening esophageal fistula during radiotherapy.

Discussion: To our knowledge, this study protocol is the first to identify the sensitivity and specificity of oral meglumine diatrizoate in an esophagogram for screening esophageal fistula during radiotherapy. If oral meglumine diatrizoate can be used to screening esophageal fistula, more patients will benefit from early detection and treatment.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Overview of the diagnostic pathway for esophageal fistula by oral meglumine diatrizoate esophagogram during radiotherapy for esophageal cancer.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin 2007;57:43–66. - PubMed
    1. Chen W, Zheng R, Zeng H, et al. Annual report on status of cancer in China, 2011. Chin J Cancer Res 2015;27:2–12. - PMC - PubMed
    1. Li JY, Liu BQ, Li GY, et al. Atlas of cancer mortality in the People's Republic of China. An aid for cancer control and research. Int J Epidemiol 1981;10:127–33. - PubMed
    1. Yang C, Wang H, Wang Z, et al. Risk factors for esophageal cancer: a case-control study in South-western China. Asian Pac J Cancer Prev 2005;6:48–53. - PubMed
    1. Chu DT. Contemporary Tumor Medical Treatment Scheme Evaluation. 2nd ed.2005;Beijing: Beijing Medical University Press, 123–124.
Feedback